戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                 Bacillus anthracis can cause inhalational anthrax.
2  vivo NK cell depletion in a murine model of inhalational anthrax.
3 ignificantly attenuated in a murine model of inhalational anthrax.
4 icrobial activity, we used a murine model of inhalational anthrax.
5 ival in rabbits and monkeys with symptomatic inhalational anthrax.
6 use aerosol challenge model for the study of inhalational anthrax.
7 one and completely protected animals against inhalational anthrax.
8 urrently no approved effective treatment for inhalational anthrax.
9 tive therapy for prevention and treatment of inhalational anthrax.
10 ts toward identifying clinical predictors of inhalational anthrax.
11 s an endospore-forming bacterium that causes inhalational anthrax.
12                       The cause of death was inhalational anthrax.
13 tes, but tragically some individuals died of inhalational anthrax.
14 as been described as the classic pattern for inhalational anthrax.
15 ) in order to explain dose-response data for inhalational anthrax.
16 g was 100% sensitive (95% CI 84.6-100.0) for inhalational anthrax, 71.8% specific (64.8-78.1) compare
17                                              Inhalational anthrax, a disease caused by inhaling Bacil
18 osure to Bacillus anthracis spores initiates inhalational anthrax, a life-threatening infection.
19                                Prevention of inhalational anthrax after Bacillus anthracis spore expo
20 ber 19 and October 26, there were 5 cases of inhalational anthrax among postal workers who were emplo
21 py appears to have slowed the progression of inhalational anthrax and has resulted to date in surviva
22 otic prophylaxis required to protect against inhalational anthrax and may impact public health manage
23 osed to prophylaxis, could effectively treat inhalational anthrax and prevent disease caused by the g
24 d cough do not reliably discriminate between inhalational anthrax and viral respiratory tract infecti
25  of the central stages in the progression of inhalational anthrax, and it is commonly believed that t
26 are likely the first immune cells exposed to inhalational anthrax, and the interferon (IFN) response
27 R/MCR model with other computation models of inhalational anthrax, and using the resulting informatio
28    The cases of 2 postal workers who died of inhalational anthrax are reported here.
29  conduct credible human risk assessments for inhalational anthrax associated with exposure to a low n
30                                       During inhalational anthrax, Bacillus anthracis survives and re
31                       The etiologic agent of inhalational anthrax, Bacillus anthracis, produces virul
32 es are decisive events in the progression of inhalational anthrax because they initiate germination a
33 60 days of antibiotic prophylaxis to prevent inhalational anthrax, but adherence to this regimen was
34  York City hospital employee developed fatal inhalational anthrax, but with an unknown source of anth
35       Also, rabbits that were protected from inhalational anthrax by administration of ETI-204 develo
36 atocrit were more frequently recorded in the inhalational anthrax cases than in either the community-
37                                              Inhalational anthrax caused by Bacillus anthracis is ass
38 of patients who died of bioterrorism-related inhalational anthrax confirmed the route of infection.
39   This study demonstrated that the course of inhalational anthrax disease and the resulting pathology
40 ant importance to reassess the mechanisms of inhalational anthrax dissemination, since it is this for
41                               Mortality from inhalational anthrax during the 2001 U.S. attack was sub
42   Bacillus anthracis, the causative agent of inhalational anthrax, enters a host through the pulmonar
43 g the recent bioterrorism-related outbreaks, inhalational anthrax had a 45% mortality in spite of app
44                                              Inhalational anthrax has characteristic clinical feature
45  had been mailed to a US senator, 5 cases of inhalational anthrax have occurred among postal workers
46 adenopathy led to a presumptive diagnosis of inhalational anthrax in both cases.
47 is capsule and toxins in the pathogenesis of inhalational anthrax in rabbits by comparing infection w
48  of rPA provides complete protection against inhalational anthrax in rabbits.
49  identification of patients with presumptive inhalational anthrax in the setting of a large-scale ant
50 l history, pathophysiology, and pathology of inhalational anthrax in this animal model following nose
51 ed attenuated virulence in a murine model of inhalational anthrax infection.
52 udies aiming to understand events initiating inhalational anthrax infections.
53                          The rabbit model of inhalational anthrax is an important tool in the assessm
54                                              Inhalational anthrax is caused by inhalation of Bacillus
55                                              Inhalational anthrax is caused by the sporulating bacter
56 's high index of suspicion, the diagnosis of inhalational anthrax is difficult during nonspecific pro
57                                              Inhalational anthrax is initiated by the entry of Bacill
58 ed public health responses to an outbreak of inhalational anthrax is the optimum duration of antibiot
59 advances in supportive care, fulminant-phase inhalational anthrax is usually fatal.
60 teritis; however, some recent isolates cause inhalational anthrax-like diseases and death.
61 rax attack, mass screening to identify early inhalational anthrax may improve both the management of
62 istorical data sets from West Nile virus and inhalational anthrax outbreaks.
63 th authorities investigated 11 patients with inhalational anthrax related to a bioterrorism attack in
64 scribe the 11th case of bioterrorism-related inhalational anthrax reported in the United States.
65  has been proposed that the dissemination of inhalational anthrax required spores to be transported f
66                  Postexposure prophylaxis of inhalational anthrax requires prolonged antibiotic thera
67 CT) findings in two patients with documented inhalational anthrax resulting from bioterrorism exposur
68        In contrast to events in experimental inhalational anthrax, spore germination in these cutaneo
69 significantly attenuated in a mouse model of inhalational anthrax, suggesting that the microarray dat
70                          In the treatment of inhalational anthrax, the prolonged course of antibiotic
71 des unique insight into host defense against inhalational anthrax; these data also support the notion
72  is developed to analyze the transmission of inhalational anthrax through the postal system by cross-
73      To identify clinical characteristics of inhalational anthrax, we compared 47 historical cases (i
74       Although several factors contribute to inhalational anthrax, we hypothesized that unimpeded inf
75 CR and MCR model appeared to describe rabbit inhalational anthrax well.
76  competing risks (CR) computational model of inhalational anthrax where data was collected from NZW r
77 scription of the early infection dynamics of inhalational anthrax, while its stochastic nature allows
78 Aerosol challenge of guinea pigs resulted in inhalational anthrax with death occurring between 46 and